High Alert
Contraindicated in:
Use Cautiously in:
Use during pregnancy only if potential maternal benefit justifies potential fetal risk. Chronic maternal treatment with opioids during pregnancy may result in neonatal opioid withdrawal syndrome
;CV: hypotension, bradycardia
Derm: flushing, sweating
EENT: blurred vision, diplopia, miosis
Endo: adrenal insufficiency
GI: constipation, dry mouth, nausea, vomiting
Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)
Misc: allodynia, opioid-induced hyperalgesia,
physical dependence
,psychological dependence
, toleranceDrug-drug:
Use with benzodiazepines or other CNS depressants, including other opioids, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Drug-Natural Products:
Hepatic Impairment
Renal Impairment
Absorption: Well absorbed following oral, rectal, SUBQ, and IM administration. Extended-release product results in an initial release of drug, followed by a 2nd sustained phase of absorption.
Distribution: Widely distributed to tissues.
Half-Life: Oral (immediate release) or injection: 24 hr; Oral (extended release): 815 hr.
(analgesic effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO-IR | 30 min | 3090 min | 45 hr |
PO-ER | unknown | unknown | unknown |
SUBQ | 15 min | 3090 min | 45 hr |
IM | 15 min | 3060 min | 45 hr |
IV | 1015 min | 1530 min | 23 hr |
Rect | 1530 min | 3090 min | 45 hr |
Advise patient to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Inform patient of potential for neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Monitor neonate for signs and symptoms of withdrawal symptoms (irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, failure to gain weight); usually occur the first days after birth. Monitor infants exposed to hydromorphone through breast milk for excess sedation and respiratory depression. Chronic use may ↓ fertility in women and men.
NDC Code